WGS · GeneDx Holdings Corp.

$78.08 -1.07 (-1.35%) At close · Aug 14

Market Cap

$2.33B

29.82M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Katherine Stueland	Chief Executive Officer	$715,869	—	$11,738,600	—	$1,075,500	$17,250	$13,547,219
Kevin Feeley	Chief Financial Officer	$500,600	—	$3,756,926	—	$414,150	$17,250	$4,688,926

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Katherine Stueland	CEO	$675,000	$950,000	$2,796,800	—	—	—	$4,421,800
Kevin Feeley	CFO	$450,000	$315,000	$568,100	—	—	$16,500	$1,349,600
Jason Ryan	Board Chair	$6,490	—	$338,480	—	—	$96,500	$441,470
Bryan Dechairo	Chief Operating Officer	—	—	—	—	—	—	—

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Katherine Stueland	CEO	$675,000	—	$2,829,420	—	—	—	$3,504,420
Kevin Feeley	CFO	$450,000	—	$1,086,035	—	—	$16,500	$1,552,535
Kareem Saad	Chief Transformation Officer	$375,000	—	$771,658	—	—	$41,360	$1,188,018
Jason Ryan	Board Chair	$343,471	—	$628,754	—	—	$16,500	$988,725
Bryan Dechairo	Chief Operating Officer	—	—	—	—	—	—	—

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Katherine Stueland	Chief Executive Officer	$453,557	$573,800	$5,445,707	$5,397,727	—	$11,563	$11,882,354
Kevin Feeley	Chief Financial Officer	$294,231	$191,300	$1,605,679	$1,542,770	—	$23,700	$3,657,680
Jason Ryan	Chairman of the Board	$510,923	$108,000	$1,658,374	$876,649	—	$39,515	$3,193,461
Kareem Saad	Chief Transformation Officer	$375,000	$34,000	$849,833	$762,927	—	$45,269	$2,067,029

Executive changes

Person	Role	Change	Effective	Filed
Mark Gardner	President	Appointed	2026-06-15	2026-06-16
Thomas Fuchs	Class I director	Appointed	2025-09-17	2025-09-18
Bryan Dechairo, Ph.D.	Chief Operating Officer	Appointed	2025-01-02	2025-01-02
Dr. Michael Pellini	Board of Directors	Resigned	2023-02-14	2023-02-14
Kevin Feeley	Chief Financial Officer	Appointed	2022-08-25	2022-08-26
Shawn Assad	Chief Accounting Officer	Resigned	2022-08-30	2022-07-01
Richard Miao	interim Chief Financial Officer	Appointed	—	2022-06-14
Richard Miao	Interim Chief Financial Officer	Appointed	2022-06-13	2022-06-14
Katherine Stueland	CEO	Appointed	2022-05-02	2022-05-02
Eric Schadt	Board of Directors	Appointed	—	2022-05-02
Eric Schadt	President and Chief Research & Development Officer	Appointed	—	2022-05-02
Katherine Stueland	Board of Directors	Appointed	—	2022-05-02
Katherine Stueland	CEO	Appointed	—	2022-05-02
Katherine Stueland	Co-Chief Executive Officer	Appointed	2022-04-29	2022-05-02
Eric Schadt	President and Chief Research & Development Officer	Appointed	2022-04-29	2022-05-02
Richard P. Pfenniger	Class III directors	Appointed	2022-04-29	2022-05-02
Eric Schadt	Chief Executive Officer	Resigned	2022-04-29	2022-05-02
Katherine Stueland	Class III directors	Appointed	2022-04-29	2022-05-02
Nat Turner	Board of Directors	Resigned	2022-04-29	2022-05-02

Key facts CIK 1818331 CUSIP 81663L200 13F (30d) 216 filings 211 filers Visit website Investor relations